Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Viking2233on Mar 15, 2024 4:37pm

169 Views

Post# 35935717

More great News today

with 1 Canadian site in Calgary and two more coming plus additional 3 sites in Turkey which will bring us to 9. It will be a big bonus if we get a few USA sites get us to 12-15 total sites.

Momentum iis definitely shifting, volume increasing daily and I feel the short squeeze has begun.

We closed at $2.20 today and are up 26% for the week which is awesome. We are only .18 cents away from 52 week high of $2.38 and would not be surprised we hit new 52 week high next week.

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition